Enrique Alvarez
Concepts (306)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 46 | 2026 | 484 | 8.600 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 16 | 2026 | 82 | 3.900 |
Why?
| | Immunologic Factors | 9 | 2026 | 255 | 3.270 |
Why?
| | Fingolimod Hydrochloride | 6 | 2020 | 39 | 2.160 |
Why?
| | Natalizumab | 5 | 2023 | 41 | 2.100 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 6 | 2023 | 28 | 2.010 |
Why?
| | Rituximab | 7 | 2025 | 210 | 1.860 |
Why?
| | Immunosuppressive Agents | 9 | 2024 | 847 | 1.260 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2025 | 988 | 0.990 |
Why?
| | Agammaglobulinemia | 2 | 2023 | 36 | 0.950 |
Why?
| | Dimethyl Fumarate | 3 | 2020 | 12 | 0.950 |
Why?
| | Drug Substitution | 2 | 2025 | 63 | 0.930 |
Why?
| | Oligoclonal Bands | 3 | 2026 | 26 | 0.730 |
Why?
| | Neuromyelitis Optica | 4 | 2020 | 138 | 0.680 |
Why?
| | Serum Sickness | 1 | 2019 | 4 | 0.610 |
Why?
| | Magnetic Resonance Imaging | 12 | 2026 | 3869 | 0.580 |
Why?
| | Adult | 38 | 2026 | 40506 | 0.510 |
Why?
| | Medical Marijuana | 1 | 2018 | 123 | 0.490 |
Why?
| | Middle Aged | 37 | 2026 | 35928 | 0.490 |
Why?
| | Lymphocyte Depletion | 3 | 2021 | 132 | 0.480 |
Why?
| | Antigens, CD20 | 3 | 2025 | 35 | 0.470 |
Why?
| | Antibodies, Monoclonal | 5 | 2026 | 1524 | 0.470 |
Why?
| | Biomarkers | 6 | 2026 | 4275 | 0.470 |
Why?
| | Pregnancy Complications | 2 | 2018 | 592 | 0.470 |
Why?
| | Axons | 2 | 2014 | 201 | 0.460 |
Why?
| | Humans | 66 | 2026 | 144957 | 0.450 |
Why?
| | Marijuana Smoking | 1 | 2018 | 250 | 0.450 |
Why?
| | Neurofilament Proteins | 1 | 2014 | 80 | 0.420 |
Why?
| | Female | 44 | 2026 | 78376 | 0.410 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1054 | 0.390 |
Why?
| | Anemia | 1 | 2015 | 188 | 0.390 |
Why?
| | Chemokine CXCL13 | 1 | 2013 | 15 | 0.390 |
Why?
| | Recurrence | 6 | 2024 | 1135 | 0.370 |
Why?
| | Male | 40 | 2026 | 72406 | 0.360 |
Why?
| | Brain | 9 | 2026 | 2941 | 0.320 |
Why?
| | Demyelinating Diseases | 4 | 2026 | 84 | 0.320 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1982 | 0.300 |
Why?
| | Immunoglobulin G | 4 | 2026 | 893 | 0.290 |
Why?
| | Muscle, Skeletal | 6 | 2026 | 1796 | 0.280 |
Why?
| | Glatiramer Acetate | 2 | 2019 | 18 | 0.270 |
Why?
| | Injections, Subcutaneous | 2 | 2025 | 164 | 0.270 |
Why?
| | Walking | 4 | 2023 | 545 | 0.270 |
Why?
| | Killer Cells, Natural | 3 | 2021 | 469 | 0.270 |
Why?
| | Neuroimaging | 2 | 2026 | 292 | 0.240 |
Why?
| | Leukoencephalopathies | 1 | 2026 | 24 | 0.240 |
Why?
| | Fatigue | 3 | 2026 | 366 | 0.240 |
Why?
| | B-Lymphocytes | 3 | 2023 | 877 | 0.230 |
Why?
| | Patient Preference | 2 | 2026 | 225 | 0.230 |
Why?
| | Neurons | 4 | 2026 | 1642 | 0.220 |
Why?
| | Chromosomes, Human, X | 1 | 2005 | 76 | 0.220 |
Why?
| | Treatment Outcome | 10 | 2026 | 11695 | 0.220 |
Why?
| | Remyelination | 1 | 2025 | 15 | 0.220 |
Why?
| | Administration, Intravenous | 1 | 2025 | 170 | 0.220 |
Why?
| | Multigene Family | 1 | 2005 | 204 | 0.220 |
Why?
| | Decision Making | 2 | 2026 | 980 | 0.220 |
Why?
| | Immunoglobulin A | 1 | 2026 | 214 | 0.220 |
Why?
| | Retrospective Studies | 10 | 2025 | 17101 | 0.210 |
Why?
| | White Matter | 1 | 2026 | 154 | 0.210 |
Why?
| | Isometric Contraction | 1 | 2026 | 188 | 0.200 |
Why?
| | Central Nervous System | 1 | 2026 | 281 | 0.200 |
Why?
| | Atrophy | 2 | 2021 | 201 | 0.200 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2003 | 70 | 0.200 |
Why?
| | Neuroprotection | 1 | 2023 | 46 | 0.200 |
Why?
| | Diphosphonates | 1 | 2003 | 68 | 0.190 |
Why?
| | Bone Resorption | 1 | 2003 | 80 | 0.190 |
Why?
| | Alemtuzumab | 1 | 2023 | 15 | 0.190 |
Why?
| | Nitro Compounds | 1 | 2023 | 8 | 0.190 |
Why?
| | Myelin Sheath | 1 | 2025 | 168 | 0.190 |
Why?
| | Disease Progression | 7 | 2026 | 2852 | 0.190 |
Why?
| | Quality of Life | 5 | 2026 | 3192 | 0.190 |
Why?
| | Cellular Senescence | 1 | 2025 | 226 | 0.190 |
Why?
| | Microglia | 1 | 2025 | 269 | 0.180 |
Why?
| | Thiazoles | 1 | 2023 | 136 | 0.180 |
Why?
| | Double-Blind Method | 6 | 2026 | 2029 | 0.180 |
Why?
| | Gadolinium | 2 | 2022 | 84 | 0.180 |
Why?
| | Interoception | 1 | 2021 | 3 | 0.180 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2026 | 851 | 0.170 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 592 | 0.170 |
Why?
| | Diagnostic Self Evaluation | 1 | 2021 | 24 | 0.170 |
Why?
| | Neuroblastoma | 1 | 2023 | 174 | 0.170 |
Why?
| | Drug Costs | 1 | 2023 | 116 | 0.170 |
Why?
| | Stair Climbing | 1 | 2021 | 2 | 0.170 |
Why?
| | Inflammation | 1 | 2013 | 2880 | 0.170 |
Why?
| | Crotonates | 3 | 2026 | 7 | 0.170 |
Why?
| | Toluidines | 3 | 2026 | 10 | 0.170 |
Why?
| | Hydroxybutyrates | 3 | 2026 | 15 | 0.170 |
Why?
| | Resistance Training | 1 | 2024 | 182 | 0.170 |
Why?
| | Young Adult | 7 | 2026 | 14126 | 0.160 |
Why?
| | Lymphopenia | 1 | 2020 | 65 | 0.160 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2005 | 906 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2023 | 784 | 0.160 |
Why?
| | Hippocampus | 3 | 2002 | 967 | 0.150 |
Why?
| | Personality | 1 | 2021 | 132 | 0.150 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 154 | 0.150 |
Why?
| | Torso | 1 | 2020 | 36 | 0.150 |
Why?
| | Cancer Vaccines | 1 | 2021 | 160 | 0.150 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2002 | 108 | 0.150 |
Why?
| | Nitriles | 3 | 2026 | 205 | 0.150 |
Why?
| | Neutropenia | 1 | 2020 | 155 | 0.150 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2019 | 23 | 0.150 |
Why?
| | Muscle Strength | 2 | 2024 | 330 | 0.150 |
Why?
| | Disease Management | 1 | 2023 | 647 | 0.150 |
Why?
| | Transforming Growth Factor beta | 2 | 2017 | 479 | 0.150 |
Why?
| | Receptors, Glutamate | 1 | 1999 | 26 | 0.150 |
Why?
| | Sodium Glutamate | 1 | 1999 | 12 | 0.140 |
Why?
| | Pelvis | 1 | 2020 | 124 | 0.140 |
Why?
| | Avoidance Learning | 1 | 1999 | 65 | 0.140 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2018 | 73 | 0.140 |
Why?
| | Nerve Net | 1 | 2021 | 285 | 0.140 |
Why?
| | Muscle Spasticity | 1 | 2018 | 63 | 0.140 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 257 | 0.130 |
Why?
| | Cognition | 1 | 2026 | 1269 | 0.130 |
Why?
| | Dendritic Cells | 1 | 2021 | 499 | 0.130 |
Why?
| | Immunotherapy, Adoptive | 1 | 2021 | 337 | 0.130 |
Why?
| | Electric Stimulation Therapy | 1 | 2018 | 63 | 0.130 |
Why?
| | Reaction Time | 1 | 1999 | 438 | 0.130 |
Why?
| | Interferon beta-1a | 1 | 2016 | 14 | 0.130 |
Why?
| | Gait | 1 | 2020 | 313 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 415 | 0.120 |
Why?
| | Psychomotor Performance | 1 | 2019 | 328 | 0.120 |
Why?
| | Postural Balance | 1 | 2019 | 240 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2020 | 5417 | 0.120 |
Why?
| | Lymphocyte Activation | 2 | 2019 | 1126 | 0.120 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2017 | 88 | 0.120 |
Why?
| | Transcription Factor RelA | 1 | 2016 | 85 | 0.120 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 783 | 0.120 |
Why?
| | Patient Care Planning | 1 | 2017 | 170 | 0.120 |
Why?
| | CD40 Antigens | 1 | 2016 | 90 | 0.120 |
Why?
| | Mycophenolic Acid | 1 | 2016 | 120 | 0.120 |
Why?
| | Prospective Studies | 2 | 2025 | 7997 | 0.120 |
Why?
| | Movement | 3 | 2023 | 294 | 0.110 |
Why?
| | Contrast Media | 1 | 2018 | 488 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 940 | 0.110 |
Why?
| | Survival Analysis | 1 | 2018 | 1385 | 0.110 |
Why?
| | Postpartum Period | 1 | 2017 | 365 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 311 | 0.110 |
Why?
| | Monocytes | 1 | 2017 | 538 | 0.100 |
Why?
| | Melanoma | 1 | 2021 | 761 | 0.100 |
Why?
| | Proteomics | 3 | 2026 | 1195 | 0.100 |
Why?
| | Pyridines | 1 | 2018 | 605 | 0.100 |
Why?
| | Disability Evaluation | 4 | 2018 | 310 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2021 | 847 | 0.100 |
Why?
| | Patient Participation | 1 | 2017 | 433 | 0.100 |
Why?
| | Pain | 1 | 2018 | 782 | 0.100 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2017 | 300 | 0.090 |
Why?
| | Aged | 7 | 2026 | 25947 | 0.090 |
Why?
| | Rats | 5 | 2005 | 5614 | 0.090 |
Why?
| | Dopamine | 2 | 2005 | 289 | 0.090 |
Why?
| | Adolescent | 5 | 2026 | 22453 | 0.090 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2011 | 38 | 0.080 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 97 | 0.080 |
Why?
| | Time Factors | 2 | 2021 | 7183 | 0.080 |
Why?
| | Antigen-Presenting Cells | 1 | 2011 | 160 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2017 | 1167 | 0.080 |
Why?
| | Infusions, Intravenous | 2 | 2023 | 423 | 0.080 |
Why?
| | Health Personnel | 1 | 2017 | 748 | 0.080 |
Why?
| | Hypoxia | 1 | 2017 | 1199 | 0.080 |
Why?
| | Leukocytes | 1 | 2011 | 295 | 0.080 |
Why?
| | Animals | 8 | 2025 | 38109 | 0.070 |
Why?
| | Lymphocytes | 1 | 2011 | 382 | 0.070 |
Why?
| | Cross-Sectional Studies | 4 | 2026 | 5872 | 0.070 |
Why?
| | Neoplasms | 1 | 2024 | 2884 | 0.070 |
Why?
| | Pregnancy | 2 | 2018 | 7191 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2013 | 3608 | 0.070 |
Why?
| | Spinal Cord | 2 | 2012 | 382 | 0.070 |
Why?
| | MicroRNAs | 1 | 2013 | 701 | 0.060 |
Why?
| | Biomechanical Phenomena | 2 | 2021 | 842 | 0.060 |
Why?
| | Rats, Inbred F344 | 2 | 2003 | 268 | 0.060 |
Why?
| | Microinjections | 3 | 2002 | 92 | 0.060 |
Why?
| | Incidental Findings | 1 | 2026 | 80 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 52 | 0.060 |
Why?
| | Glycosylation | 1 | 2026 | 172 | 0.060 |
Why?
| | Immunologic Memory | 2 | 2019 | 366 | 0.060 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2005 | 157 | 0.060 |
Why?
| | Protein Aggregates | 1 | 2026 | 86 | 0.060 |
Why?
| | Cohort Studies | 3 | 2026 | 5965 | 0.060 |
Why?
| | Chemokine CCL11 | 1 | 2025 | 25 | 0.060 |
Why?
| | Immunoglobulin M | 1 | 2026 | 284 | 0.050 |
Why?
| | Organ Specificity | 1 | 2005 | 313 | 0.050 |
Why?
| | Pilot Projects | 2 | 2021 | 1890 | 0.050 |
Why?
| | Cytoplasm | 1 | 2005 | 269 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2005 | 159 | 0.050 |
Why?
| | Species Specificity | 1 | 2005 | 574 | 0.050 |
Why?
| | Risk Factors | 1 | 2018 | 10792 | 0.050 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2003 | 25 | 0.050 |
Why?
| | Electric Stimulation | 2 | 2021 | 276 | 0.050 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2004 | 71 | 0.050 |
Why?
| | Osteolysis | 1 | 2003 | 16 | 0.050 |
Why?
| | Nerve Growth Factors | 1 | 2004 | 78 | 0.050 |
Why?
| | Electromyography | 1 | 2026 | 415 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 758 | 0.050 |
Why?
| | Models, Biological | 1 | 2011 | 1822 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 2065 | 0.050 |
Why?
| | Pluripotent Stem Cells | 1 | 2004 | 84 | 0.050 |
Why?
| | Depression | 2 | 2026 | 1559 | 0.050 |
Why?
| | Clinical Trials, Phase IV as Topic | 1 | 2022 | 3 | 0.050 |
Why?
| | Oligodendroglia | 1 | 2025 | 187 | 0.050 |
Why?
| | Mice | 3 | 2025 | 18365 | 0.050 |
Why?
| | Aging | 2 | 2025 | 1966 | 0.050 |
Why?
| | Kynurenic Acid | 1 | 2002 | 18 | 0.050 |
Why?
| | Arm | 1 | 2023 | 110 | 0.050 |
Why?
| | Intermediate Filaments | 1 | 2022 | 25 | 0.050 |
Why?
| | Histamine | 1 | 1982 | 53 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2005 | 619 | 0.040 |
Why?
| | Maze Learning | 1 | 2002 | 104 | 0.040 |
Why?
| | Arthritis, Rheumatoid | 1 | 2011 | 1169 | 0.040 |
Why?
| | Behavior, Animal | 2 | 2002 | 520 | 0.040 |
Why?
| | Cell Division | 1 | 2003 | 766 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2023 | 134 | 0.040 |
Why?
| | Base Sequence | 1 | 2005 | 2191 | 0.040 |
Why?
| | Regional Blood Flow | 1 | 2024 | 514 | 0.040 |
Why?
| | MART-1 Antigen | 1 | 2021 | 8 | 0.040 |
Why?
| | Heart | 1 | 2005 | 636 | 0.040 |
Why?
| | Gray Matter | 1 | 2022 | 92 | 0.040 |
Why?
| | Research Report | 1 | 2021 | 87 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 695 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2931 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 405 | 0.040 |
Why?
| | Cell Survival | 1 | 2003 | 1098 | 0.040 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2002 | 228 | 0.040 |
Why?
| | Long-Term Potentiation | 1 | 2002 | 200 | 0.040 |
Why?
| | Mobility Limitation | 1 | 2020 | 66 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2023 | 316 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 338 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2024 | 1095 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 672 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2019 | 164 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 42 | 0.040 |
Why?
| | Indolizines | 1 | 2018 | 13 | 0.040 |
Why?
| | Adaptation, Physiological | 1 | 2023 | 570 | 0.040 |
Why?
| | Motor Skills | 1 | 2019 | 104 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 87 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1786 | 0.030 |
Why?
| | Hand | 1 | 2019 | 161 | 0.030 |
Why?
| | Diffusion Tensor Imaging | 1 | 2018 | 73 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1268 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2019 | 148 | 0.030 |
Why?
| | Leg | 1 | 2019 | 239 | 0.030 |
Why?
| | Homeostasis | 1 | 2021 | 640 | 0.030 |
Why?
| | Headache | 1 | 2018 | 150 | 0.030 |
Why?
| | Organ Size | 1 | 2018 | 463 | 0.030 |
Why?
| | Knee Joint | 1 | 2021 | 426 | 0.030 |
Why?
| | Macrophages | 1 | 2025 | 1511 | 0.030 |
Why?
| | Tumor Escape | 1 | 2017 | 49 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1465 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2017 | 223 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1888 | 0.030 |
Why?
| | Internet | 1 | 2021 | 700 | 0.030 |
Why?
| | Memory | 1 | 1999 | 296 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 216 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2019 | 389 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2017 | 521 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 173 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2004 | 2050 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1721 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2003 | 3550 | 0.030 |
Why?
| | Risk | 1 | 2017 | 911 | 0.030 |
Why?
| | Pyrazoles | 1 | 2018 | 510 | 0.030 |
Why?
| | Apoptosis | 1 | 2023 | 2430 | 0.030 |
Why?
| | Focus Groups | 1 | 2017 | 573 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 359 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 5997 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1048 | 0.020 |
Why?
| | Incidence | 1 | 2020 | 2883 | 0.020 |
Why?
| | Prognosis | 1 | 2022 | 4293 | 0.020 |
Why?
| | Genetic Markers | 1 | 2013 | 331 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1327 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 2197 | 0.020 |
Why?
| | Patient-Centered Care | 1 | 2017 | 544 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1733 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1695 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 427 | 0.020 |
Why?
| | Down-Regulation | 1 | 2013 | 627 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2023 | 6434 | 0.020 |
Why?
| | Pain Measurement | 1 | 2012 | 555 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 1177 | 0.020 |
Why?
| | Pain Management | 1 | 2012 | 405 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2118 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8279 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2925 | 0.010 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2004 | 17 | 0.010 |
Why?
| | Cell Shape | 1 | 2004 | 57 | 0.010 |
Why?
| | Mesencephalon | 1 | 2004 | 65 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 2004 | 111 | 0.010 |
Why?
| | Stromal Cells | 1 | 2004 | 125 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2004 | 246 | 0.010 |
Why?
| | Grooming | 1 | 1982 | 9 | 0.010 |
Why?
| | Stem Cell Transplantation | 1 | 2004 | 191 | 0.010 |
Why?
| | Spermine | 1 | 2002 | 29 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1982 | 321 | 0.010 |
Why?
| | Corpus Striatum | 1 | 2004 | 179 | 0.010 |
Why?
| | Oligonucleotides, Antisense | 1 | 2002 | 116 | 0.010 |
Why?
| | Astrocytes | 1 | 2004 | 224 | 0.010 |
Why?
| | Excitatory Postsynaptic Potentials | 1 | 2002 | 117 | 0.010 |
Why?
| | Catheterization | 1 | 2002 | 183 | 0.010 |
Why?
| | Locomotion | 1 | 1982 | 105 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2002 | 165 | 0.010 |
Why?
| | United States | 1 | 2018 | 15988 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1048 | 0.010 |
Why?
| | Blotting, Western | 1 | 2002 | 1187 | 0.010 |
Why?
| | Action Potentials | 1 | 2002 | 507 | 0.010 |
Why?
| | Parkinson Disease | 1 | 2004 | 600 | 0.010 |
Why?
| | Gene Expression | 1 | 2002 | 1490 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2004 | 2499 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 4155 | 0.010 |
Why?
| | Phenotype | 1 | 2004 | 3164 | 0.010 |
Why?
|
|
Alvarez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|